tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Dr. Gerald Crabtree'

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly

Written by ι Stock Market Media Group Staff — February 24, 2014

Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be viewed as a $27 million “pot of money” to advance the company’s late-phase pancreatic cancer clinical trials.  Notice we said restricted shares, that’s right, LPC has put a great deal of its money on the line with a number of built in protections for Nuvilex.  ...

Read More →
0

Move over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials

Move over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials

Written by ι Stock Market Media Group Staff — February 21, 2014

Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry.  The company can now move forward with its clinical trials for the treatment of advanced inoperable pancreatic cancer after Nuvilex landed a $27 million funding deal that could change the sector for years to come.  Funding is always the biggest hurdle for any small biotechnology or pharmaceutical firm, and its why larger firms with competing treatments can often sit back ...

Read More →
0

Nuvilex’s Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials

Nuvilex’s Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials

Written by ι Stock Market Media Group Staff — February 19, 2014

Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and pharmaceutical companies like Eli Lilly and Celgene. If the company’s pancreatic cancer treatment that combines the proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box™ with the anti-cancer drug ifosfamide can produce the same or better data in its upcoming late-phase clinical trials in advanced, inoperable pancreatic cancer than ...

Read More →
0

Congressional Legislators Agree with Nuvilex’s Dr. Mark Rabe on Reclassifying Marijuana

Written by ι Stock Market Media Group — February 14, 2014

Nuvilex, Inc.’s (OTCQB: NVLX) Dr. Mark L. Rabe has something in common with 18 members of Congress.  All of them want marijuana reclassified from its current listing as a dangerous drug with no medical value, and they want President Obama to use his authority to make that change by removing marijuana from the Schedule I category.  Currently marijuana is viewed in the same category as drugs like heroin and LSD, and in ...

Read More →
0

After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment

After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment

Written by ι Stock Market Media Group Staff — December 5, 2013

Eli Lilly & Co. (NYSE: LLY) has parlayed its cancer drug Gemzar® or gemcitabine into well over $10 billion since it gained approval to treat advanced, inoperable pancreatic cancer back in 1996.  Meanwhile, Nuvilex, Inc. (OTCQB: NVLX) has its eyes on a piece of that billion dollar pie with the company’s live-cell encapsulation based treatment for pancreatic cancer.  But, it may be another disease that has these two biotech’s going head ...

Read More →
0

New Study Continues to Validate Nuvilex’s Approach to Medical Marijuana Research

New Study Continues to Validate Nuvilex’s Approach to Medical Marijuana Research

Written by ι Stock Market Media Group Staff — October 22, 2013

Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., received another validation of their efforts to bring research utilizing cannabidiol (CBD) as the basis for developing treatments for some of the deadliest forms of cancer to the industry.  This latest study serves as another piece of evidence in a mounting argument that cannabinoids from Cannabis, such as CBD, are effective anti-cancer drugs.   

It was a team at St ...

Read More →
0
Page 1 of 2 12
ContactUs.com